3-[(Tetradec-5-enoyl)oxy]-4-(trimethylazaniumyl)butanoate | 835598-21-5

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 3-[(Tetradec-5-enoyl)oxy]-4-(trimethylazaniumyl)butanoate
• 英文别名: 3-tetradec-5-enoyloxy-4-(trimethylazaniumyl)butanoate
• CAS: 835598-21-5
• 化学式: C21H39NO4
• 分子量: 369.5
• InChiKey: NNCBVXBBLABOCB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.7
• 重原子数：
  26
• 可旋转键数：
  16
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.81
• 拓扑面积：
  66.4
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• Compositions and methods for improving skin health and for the treatment and prevention of diseases, disorders and conditions associated with pathogenic microbes
  申请人：DermBiont, Inc.

  公开号：US11040077B2

  公开（公告）日：2021-06-22

  Disclosed herein are compositions and methods for using human-derived Janthinobacterium lividum. Compositions improve skin health. Methods may include applying human-derived Janthinobacterium lividum over a host or host area, such as skin or mucosa, to minimize the presence of one or more microbes, maximize therapeutic effects, and/or improve health. A method to minimize a pathogenic microbe may include applying to a surface a composition including human-derived Janthinobacterium lividum and an acceptable carrier. Compositions and methods may include a prebiotic to maximize growth and/or metabolites. Compositions and methods may include human-derived Janthinobacterium lividum metabolites, such as violacein, prodigiosin, indole-3-carboxaldehyde, and lantibiotics, and/or other Postbiotics.

  本文公开了使用源自人类的 Lividum Janthinobacterium 的组合物和方法。组合物可改善皮肤健康。方法可包括在宿主或宿主区域（如皮肤或粘膜）上施用源于人的生发的Lividum Janthinobacterium，以最大限度地减少一种或多种微生物的存在，最大限度地提高治疗效果，和/或改善健康状况。减少病原微生物的方法可包括向表面施用一种组合物，该组合物包括来源于人类的Janthinobacterium lividum和一种可接受的载体。组合物和方法可包括益生元，以最大限度地提高生长和/或代谢物。组合物和方法可包括来源于人的猪蓝细菌代谢物，如violacein、prodigiosin、吲哚-3-甲醛、兰特益生菌和/或其他后益生菌。
• [EN] USE OF BIOMARKER IN PREPARATION OF LUNG CANCER DETECTION REAGENT AND RELATED METHOD<br/>[FR] UTILISATION D'UN BIOMARQUEUR DANS LA PRÉPARATION D'UN RÉACTIF DE DÉTECTION DU CANCER DU POUMON ET PRODUIT ASSOCIÉ<br/>[ZH] 生物标志物在制备肺癌检测试剂中的用途和方法
  申请人：[en]SUN YAT-SEN UNIVERSITY CANCER CENTER (THE AFFILIATED CANCER HOSPITAL OF SUN YAT-SEN UNIVERSITY, THE CANCER RESEARCH INSTITUTE OF SUN YAT-SEN UNIVERSITY);[zh]中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所）

  公开号：WO2022073502A1

  公开（公告）日：2022-04-14

  利用血清代谢组学筛选出用于肺癌检测的生物标志物。提供鉴别诊断肺癌和健康人、肺癌和肺部良性肺结节病人的生物标志物，并根据性别差异提供了用于男性或女性的鉴别诊断肺癌和健康人、肺癌和肺部良性肺结节病人的生物标志物。在肺部有结节病人是否患有肺癌的鉴别诊断上，提供的生物标志物具有重要意义。
• REAGENTS AND METHODS FOR USING HUMAN EMBRYONIC STEM CELLS TO EVALUATE TOXICITY OF PHARMACEUTICAL COMPOUNDS&OTHER CHEMICALS
  申请人：WISCONSIN ALUMNI RESEARCH FOUNDATION

  公开号：EP2013619A2

  公开（公告）日：2009-01-14
• METHODS FOR USING HUMAN EMBRYONIC STEM CELLS TO EVALUATE TOXICITY OF PHARMACEUTICAL COMPOUNDS & OTHER CHEMICALS
  申请人：WISCONSIN ALUMNI RESEARCH FOUNDATION

  公开号：EP2013619B1

  公开（公告）日：2017-10-11
• Reagents and Methods for Using Human Embryonic Stem Cells to Evaluate Toxicity of Pharmaceutical Compounds and Other Chemicals
  申请人：Cezar G. Gabriela

  公开号：US20070248947A1

  公开（公告）日：2007-10-25

  The invention provides biomarker profiles of cellular metabolites and methods for screening chemical compounds including pharmaceutical agents, lead and candidate drug compounds and other chemicals using human embryonic stem cells (hESC) or lineage-specific cells produced therefrom. The inventive methods are useful for testing toxicity, particularly developmental toxicity and detecting teratogenic effects of such chemical compounds.